An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children
Condition: InfluenzaInterventions: Biological: Influenza vaccine GSK2321138A; Biological: Havrix Junior; Biological: Prevenar 13; Biological: Varivax/ProVarivax; Biological: VarilrixSponsor: GlaxoSmithKlineCompleted - verified February 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Children | Influenza | Influenza Vaccine | Research | Study | Vaccines | Varicella Virus Vaccine